Is MOLN or RLAY more undervalued in 2026?

CirclFi compares Molecular Partners AG (MOLN) and Relay Therapeutics, Inc. (RLAY) using 13 institutional-grade valuation models. MOLN has a Quality of Company score of 4.7/10 while RLAY scores 6.0/10.

Which is a better buy — MOLN or RLAY?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do MOLN and RLAY valuations compare?

MOLN at $4.00 and RLAY at $13.90 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

MOLN vs RLAY Valuation Comparison 2026 — Intrinsic Value Analysis

MOLN

Biological Products, (No Diagnostic Substances)

Molecular Partners AG

Quality

4.7

out of 10

Value Trap

LOW

Price

$4.00

Last close

Models

8/13

Active

RLAY

Biological Products, (No Diagnostic Substances)

Relay Therapeutics, Inc.

Quality

6.0

out of 10

Value Trap

SAFE

Price

$13.90

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	MOLN Fair Value	MOLN Upside	RLAY Fair Value	RLAY Upside
Bayesian DCF	Intrinsic	$1.13	-71.8%	$5.06	-63.6%
Earnings Power Value	Intrinsic	—	—	$7.19	-52.5%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
Markov DDM	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$1.69	-57.9%	$3.96	-71.5%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for MOLN vs RLAY — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

MOLN vs RLAY — Which Stock Is More Undervalued?

RLAY scores higher with a 6.0/10 quality rating vs MOLN's 4.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Molecular Partners AG (MOLN) and Relay Therapeutics, Inc. (RLAY) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

MOLN currently trades at $4.00 with a QOC of 4.7/10, while RLAY trades at $13.90 with a QOC of 6.0/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).